{
  "id": 3496972,
  "title": "Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data",
  "url": "https://urgent.news/2026/08/26/spyre-drops-rheumatoid-arthritis-hopes-for-anti-tl1a-drug-after",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-26T11:00:53.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/spyre-drops-rheumatoid-arthritis-hopes-for-anti-tl1a-drug-after-modest-phase-2-data/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Spyre Therapeutics said Tuesday it is deprioritizing its antibody candidate for rheumatoid arthritis (RA) after the drug missed the biotech’s bar for success in a mid-stage trial. The results also put a dampener on the ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Spyre reports mixed phase 2 results for SPY072 in arthritis",
        "url": "https://urgent.news/2026/08/25/spyre-reports-mixed-phase-2-results-for-spy072-in-arthritis",
        "published": "2026-08-25T20:04:37.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}